Detail akcie Photocure online

Business Summary: Photocure ASA is a Norway-based company active in the pharmaceutical industry. The Company is focused on developing and improving photodynamic technology and owns a Photocure Technology platform, which develops photodynamic technology for diagnosis and therapy. Based on the Photocure Technology platform, Photocure has developed and commercialized Hexvix (Hyperthermic IntraVEsical Chemotherapy) and Cysview (hexaminolevulinate HCL) for use in bladder cancer. The Company’s activities are divided into two business segments: The Commercial Franchise and The Development Portfolio. The Commercial Franchise segment includes Hexvix/Cysview by geography (U.S. and Europe) and other sales (partners and other products including sales revenues for Hivec). The Development Portfolio segment includes development of pipeline products.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2023, Photocure ASA revenues increased 27% to NOK500.7M. Net income applicable to common stockholders totaled NOK267K vs. loss of NOK71.9M. Revenues reflect Sales revenues increase of 19% to NOK446.2M, Signing fees and milestone revenues increase from NOK18.7M to NOK54.4M. Net Income reflects Indirect manufacturing expenses decrease of 18% to NOK12.6M (expense).